세계의 면역학 시장 예측(-2030년) : 약물 종류별, 적응증별, 용도별, 지역별 분석

According to Stratistics MRC, the Global Immunology Market is accounted for $98.93 billion in 2023 and is expected to reach $184.21 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Immunology is the branch of biomedical science that focuses on the study of the immune system - the complex network of cells, tissues, organs, and molecules that work together to defend the body against infections and other diseases. Immunology is a dynamic and rapidly evolving field with broad applications in medicine, ranging from infectious disease management to the treatment of autoimmune conditions and cancer.

According to British Society for Immunology, in 2018, around 400,000 people in U.K are suffering with rheumatoid arthritis.

Market Dynamics:

Driver:

Increasing prevalence of immunological disorders

Genetic factors and the aging global population play a significant role in the development of many immunological disorders. Exposure to certain environmental factors, such as infections, pollutants, and toxins, may trigger or exacerbate immunological disorders. These disorders foster a competitive environment within the immunology market. It results in a larger patient population seeking medical intervention. Thereby, the increasing prevalence of immunological disorders creates a multifaceted impact on the immunology market, driving demand, innovation, and investment in research and development.

Restraint:

Strict regulations

Regulations in the immunology market are designed to ensure the safety, efficacy, and quality of products related to immunological disorders. These regulations are complex and stringent regulatory processes for the approval of immunology drugs can result in delays and increased development costs. Regulatory hurdles may limit the number of new therapies entering the market. This could further hinder the development of novel immunological therapies and limit the overall innovation in the market.

Opportunity:

Advancements in biotechnology & immunotherapy

Novel strategies for treating a range of immunological illnesses are being introduced by developments in biotechnology and immunotherapy. They make it possible to create specialised treatments that target the underlying causes of immune diseases. Moreover, personalised treatment techniques are made possible by technological breakthroughs. Alongside these important developments in immunotherapy have been cell and gene treatments. Because of these advances, the immunology market is driven by the creation of personalized medical strategies, targeted medicines, and cutting-edge treatment methods.

Threat:

Competition from biosimilars

The introduction of biosimilars, which are lower-cost alternatives to biologic drugs, can pose a threat to the market. Increased competition may lead to pricing pressures and reduced market share for originator immunology drugs. Further, the development of alternative therapies, including small molecules and gene therapies, may also pose a threat to traditional immunology drugs. These emerging therapies could offer new treatment options and potentially capture market share.

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the immunology market. During the pandemic, immunology research was increased to understand the effects of covid on immunity and cope with the severe effects of the same. The success of various COVID-19 vaccines has highlighted the importance of immunology in addressing global health crises, potentially leading to increased investment and interest in immunology research. Also, the emergence of new variants of the SARS-CoV-2 virus has kept the spotlight on immunology, which influenced future developments in immunology market.

The monoclonal antibody segment is expected to be the largest during the forecast period

Themonoclonal antibody segment is estimated to have a lucrative growth, due to the clinical efficiency of the procedure and the high prevalence of drugs. Monoclonal antibodies are proteins made in the laboratory for binding to specific targets in the body, such as antigens. They can enhance, restore, modify, or mimic the immune system's attack on unwanted cells. Their easy government approvals and relatively low levels of risk, is further pushing the segment expansion.

The rheumatoid arthritis segment is expected to have the highest CAGR during the forecast period

The rheumatoid arthritis segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the growing geriatric population and rising R&D. Rheumatoid arthritis is a chronic inflammatory disorder that affects joints. Rheumatoid arthritis serves as a key driver for advancements in the immunology market by providing a specific focus on immune system deregulation, leading to the development of targeted therapies, diagnostic tools, and a deeper understanding of autoimmune diseases.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a well-established healthcare infrastructure. The region has the high prevalence of autoimmune diseases and chronic inflammatory conditions. Numerous pharmaceutical firms are actively involved in the research and marketing of immunology medications in the fiercely competitive North American market. Pfizer, Johnson & Johnson, Amgen, AbbVie, and other significant firms are doing well in this region market. Additionally, a greater diagnosis rate among patients in the area is probably going to support the expansion of the sector.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of autoimmune disorders. The region is home for several key players such as Genmab, Arctoris, Valo Therapeutics and BioNTech. Additionally, London estimates 7% of the U.K. population, or over 4 million individuals, have at least one autoimmune disorder. The region is also making efforts to secure approvals and launch drugs targeting autoimmune conditions. Thereon, the European market is driven by growing health-consciousness among consumers and boosted by the COVID-19 pandemic.

Key players in the market:

Some of the key players profiled in the Immunology Market include Novartis AG, Eli Lilly and Company, AbbVie Inc., Janssen Global Services LLC, UCB SA, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Aurobindo Pharma, F. Hoffmann-La Roche Limited, Astellas Pharma Inc. and Merck Sharp & Dohme Corporation.

Key Developments:

In March 2023, Eli Lilly and Company received approval from the Indian regulatory agency Directorate General of Commercial Intelligence and Statistics (DGCI). This approval allowed them to launch their drug, Copellor, for the treatment of moderate-to-severe plaque psoriasis and also for psoriatic arthritis.

In March 2022, Pfizer Inc. enhanced its product offering by acquiring Arena Pharmaceuticals, a company dedicated to developing cutting-edge therapies for various immuno-inflammatory diseases.

Drug Classes Covered:

• Immunosuppressants
• Monoclonal Antibody
• Fusion Proteins
• Polyclonal Antibody
• Other Drug Classes

Disease Indications Covered:

• Plaque Psoriasis
• Rheumatoid Arthritis
• Prophylaxis of Organ Rejection
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Inflammatory Bowel Disease
• Other Disease Indications

Applications Covered:

• Hospital
• Clinics
• Cancer Research Centers & Institutions
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Immunology Market, By Drug Class

• 5.1 Introduction
• 5.2 Immunosuppressants
• 5.3 Monoclonal Antibody
• 5.4 Fusion Proteins
• 5.5 Polyclonal Antibody
• 5.6 Other Drug Classes

6 Global Immunology Market, By Disease Indication

• 6.1 Introduction
• 6.2 Plaque Psoriasis
• 6.3 Rheumatoid Arthritis
• 6.4 Prophylaxis of Organ Rejection
• 6.5 Psoriatic Arthritis
• 6.6 Ankylosing Spondylitis
• 6.7 Inflammatory Bowel Disease
• 6.8 Other Disease Indications

7 Global Immunology Market, By Application

• 7.1 Introduction
• 7.2 Hospital
• 7.3 Clinics
• 7.4 Cancer Research Centers & Institutions
• 7.5 Other Applications

8 Global Immunology Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Novartis AG
• 10.2 Eli Lilly and Company
• 10.3 AbbVie Inc.
• 10.4 Janssen Global Services LLC
• 10.5 UCB SA
• 10.6 Amgen Inc.
• 10.7 Pfizer Inc.
• 10.8 Bristol-Myers Squibb Company
• 10.9 Aurobindo Pharma
• 10.10 F. Hoffmann-La Roche Limited
• 10.11 Astellas Pharma Inc.
• 10.12 Merck Sharp & Dohme Corporation